{"id":"NCT00455520","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy","officialTitle":"A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2007-04-03","resultsPosted":"2010-01-13","lastUpdate":"2013-07-19"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathy"],"interventions":[{"type":"DRUG","name":"CG5503","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"CG5503","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of Tapentadol (CG5503) extended release (ER) (base) compared to placebo in patients with moderate to severe pain from diabetic peripheral neuropathy.","primaryOutcome":{"measure":"Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Tapentadol ER","deltaMin":-0.1,"sd":1.69},{"arm":"Placebo","deltaMin":1.3,"sd":2.41}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23340531","21162697"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":196},"commonTop":["Nausea","Myalgia","Anxiety","Diarrhoea","Headache"]}}